A Study to Assess Safety, Tolerability and Pharmacokinetics of GLPG2737 in Healthy Subjects

Phase 1

Completed

• Conditions: Healthy
• Interventions: Drug: GLPG2737 single dose; Drug: Placebo single dose; Drug: GLPG2737 multiple dose

• Registration Number: NCT03410979
• Lead Sponsor: Galapagos NV

Brief Summary

This study is a first-in-human (FIH), Phase I, single center, randomized, double-blind, placebo-controlled, sequential group study in healthy male subjects to assess the safety, tolerability and PK of single ascending oral doses of GLPG2737 and multiple ascending oral doses of GLPG2737 administered for 14 days.

Detailed Description

Not available

Study Timeline

• Study Start: 2016-11-25
• Primary Completion: 2017-08-15
• Study Completion: 2017-08-15
• Status Verified: 2018-01
• Study First Submitted: 2018-01-19
• Study First Submitted QC: 2018-01-24
• Last Update Submitted: 2018-01-24
• Study First Posted: 2018-01-25
• Last Update Posted: 2018-01-25

Recruitment & Eligibility

• Status: COMPLETED
• Sex: Male
• Target Recruitment: 79

Inclusion Criteria

1. Male between 18-50 years of age, inclusive, on the date of signing the Informed Consent Form (ICF).

2. Judged by the investigator to be in good health based upon the results of a medical history, physical examination, vital signs, 12-lead ECG, and clinical safety laboratory tests prior to the initial study drug administration.

   Clinical safety laboratory test results must be within the laboratory reference ranges for males or test results that are outside the reference ranges for males need to be considered non clinically significant in the opinion of the investigator. One retest is allowed if deemed appropriate by the investigator.

3. Liver function tests must meet the following criteria:

   1. aspartate aminotransferase (AST), ALT or alkaline phosphatase (ALP) <1.2x the upper limit of normal (ULN)
   2. Bilirubin not greater than ULN, however documented Gilbert's syndrome is acceptable. One retest is allowed if deemed appropriate by the investigator.

4. Subject's screening ECG is considered normal or abnormal but clinically non-significant. QTcF must not exceed 450 msec. First degree heart block will not be considered as a significant abnormality.

5. Forced expiratory volume in 1 second (FEV1) ≥ 80% of predicted normal for age, gender and height at screening.

6. Discontinuation of all medications (including over-the-counter and/or prescription medication, dietary supplements, nutraceuticals, vitamins and/or herbal supplements) except occasional paracetamol (maximum dose of 2 g/day and maximum of 10 g/2 weeks) at least 2 weeks prior to the first study drug administration.

7. Negative drug and alcohol screen (opiates, methadone, cocaine, amphetamines [including ecstasy], cannabinoids, barbiturates, benzodiazepines, tricyclic antidepressants, and alcohol) prior to dosing.

8. Able and willing to comply with the prohibitions and restrictions as described in the protocol and with the contraceptive requirements as described in the protocol.

9. Able and willing to sign the ICF as approved by the IEC, prior to any screening evaluations.

Read More

Exclusion Criteria

1. Known hypersensitivity to study drug ingredients or a significant allergic reaction to any drug as determined by the investigator, such as anaphylaxis requiring hospitalization.
2. Positive serology for hepatitis B virus surface antigen (HBsAg) or hepatitis C virus (HCV) or history of hepatitis from any cause with the exception of hepatitis A.
3. History of or a current immunosuppressive condition (e.g., human immunodeficiency virus [HIV] infection type 1 and 2).
4. Clinically significant illness in the 3 months before screening.
5. Presence or having sequelae of gastrointestinal, liver (except for Gilbert's syndrome), kidney (creatinine clearance ≤ 80 mL/min using the Cockcroft-Gault formula: if calculated result ≤ 80 mL/min, a 24 hour urine collection to determine actual value can be done) or other conditions known to interfere with the absorption, distribution, metabolism, or excretion of drugs.
6. History of malignancy within the past 5 years (except for basal cell carcinoma of the skin that has been treated and with no evidence of recurrence).
7. Treatment with any drug known to have a well-defined potential for toxicity to a major organ in the last 3 months of 5-half-lives of the drug (whichever is longer) before the initial drug administration.
8. Active drug or alcohol abuse (an average intake of more than 21 glasses of wine or beer or equivalent/week) within 2 years prior to screening.
9. Participation in a drug, drug/device or biologic investigational research study within 12 weeks or 5 half-lives of the investigational drug, if the half-life is known (whichever is longer) prior to screening.
10. Any condition or circumstances that in the opinion of the investigator may make a subject unlikely or unable to complete the study or comply with study procedures and requirements.

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SEQUENTIAL

Arm && Interventions

Group	Intervention	Description
GLPG2737 single dose	GLPG2737 single dose	Single doses of GLPG2737 oral suspension at up to 5 dose levels in ascending order
Placebo single dose	Placebo single dose	Single doses of Placebo oral suspension
GLP2737 multiple dose	GLPG2737 multiple dose	Multiple doses of GLPG2737 oral suspension at up to 3 dose levels in ascending order
GLPG2737 multiple dose	GLPG2737 multiple dose	Multiple doses of Placebo oral suspension

Primary Outcome Measures

Name	Time	Method
Change versus placebo in the proportion of subjects with adverse events	Between screening and 14 days (SAD part) and 15 days (MAD part) after the last dose	To assess safety and tolerability of single and multiple ascending doses with GLPG2737 versus placebo in healthy subjects.

Secondary Outcome Measures

Name	Time	Method
Area under the plasma concentration-time curve (AUC0-t) of GLPG2737	Between Day 1 predose and 5 days after the last dose	To characterize pharmacokinetics of GLPG2737 and its metabolites after single and multiple oral doses in healthy subjects
Maximum observed plasma concentration (Cmax) of GLPG2737	Between Day 1 predose and 5 days after the last dose	To characterize pharmacokinetics of GLPG2737 and its metabolites after single and multiple oral doses in healthy subjects
Time of occurrence of Cmax for GLPG2737 (tmax)	Between Day 1 predose and 5 days after the last dose	To characterize pharmacokinetics of GLPG2737 and its metabolites after single and multiple oral doses in healthy subjects
Ratio of 4-beta-hydroxycholesterol/cholesterol in plasma after multiple oral doses in healthy subjects	Day 1 predose and Day 14	To explore the potential of CYP3A4 interaction with GLPG2737

Trial Locations

Locations (1)

PRA-EDS; 🇳🇱 Groningen, Netherlands